Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:OXB
- CUSIP: N/A
- Web: N/A
- Market Cap: £156.98 million
- Outstanding Shares: 3,083,993,000
- 50 Day Moving Avg: GBX 4.88
- 200 Day Moving Avg: GBX 4.36
- 52 Week Range: GBX 2.98 - GBX 6
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £27.78 million
- Price / Sales: 5.65
- Book Value: N/A
- Price / Book: N/A
- Average Volume: 5.12 million shs.
Frequently Asked Questions for Oxford BioMedica plc (LON:OXB)
What is Oxford BioMedica plc's stock symbol?
Oxford BioMedica plc trades on the London Stock Exchange (LON) under the ticker symbol "OXB."
Where is Oxford BioMedica plc's stock going? Where will Oxford BioMedica plc's stock price be in 2017?
2 analysts have issued 1-year target prices for Oxford BioMedica plc's shares. Their predictions range from GBX 3.30 to GBX 8. On average, they expect Oxford BioMedica plc's share price to reach GBX 5.65 in the next twelve months. View Analyst Ratings for Oxford BioMedica plc.
Who are some of Oxford BioMedica plc's key competitors?
Some companies that are related to Oxford BioMedica plc include Amerisur Resources plc (AMER), Telford Homes plc (TEF), Connect Group PLC (CNCT), Robert Walters PLC (RWA), Foxtons Group PLC (FOXT), Premier Oil PLC (PMO), TT Electronics plc (TTG), Cambian Group PLC (CMBN), Trinity Mirror plc (TNI), Speedy Hire Plc (SDY), Kenmare Resources plc (KMR), Cape PLC (CIU), Regional REIT Ltd (RGL), Next Fifteen Communications Group plc (NFC), Tharisa Plc (THS), Renew Holdings Plc (RNWH), Low & Bonar plc (LWB) and Xaar plc (XAR).
Who are Oxford BioMedica plc's key executives?
Oxford BioMedica plc's management team includes the folowing people:
- John Dawson, Chief Executive Officer, Executive Director
How do I buy Oxford BioMedica plc stock?
Shares of Oxford BioMedica plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Oxford BioMedica plc's stock price today?
MarketBeat Community Rating for Oxford BioMedica plc (LON OXB)MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Oxford BioMedica plc stock can currently be purchased for approximately GBX 5.09.
Consensus Ratings for Oxford BioMedica plc (LON:OXB) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||GBX 5.65|
Analysts' Ratings History for Oxford BioMedica plc (LON:OXB)
(Data available from 5/30/2015 forward)
|3/17/2017||Jefferies Group LLC||Reiterated Rating||Buy||GBX 8|
|3/16/2017||N+1 Singer||Reiterated Rating||Hold||GBX 3.30|
Earnings History for Oxford BioMedica plc (LON:OXB)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Oxford BioMedica plc (LON:OXB)
Current Year EPS Consensus Estimate: $-0.35 EPS
Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oxford BioMedica plc (LON:OXB)Insider Trades by Quarter for Oxford BioMedica plc (LON:OXB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/24/2017||Lorenzo Tallarigo||Insider||Buy||53,260||GBX 5||£2,663|
|4/24/2017||Lorenzo Tallarigo||Insider||Buy||54,090||GBX 5||£2,704.50|
|3/23/2017||Lorenzo Tallarigo||Insider||Buy||49,468||GBX 5||£2,473.40|
|2/24/2017||Lorenzo Tallarigo||Insider||Buy||67,165||GBX 4||£2,686.60|
|12/15/2016||Lorenzo Tallarigo||Insider||Buy||65,993||GBX 4||£2,639.72|
|11/25/2016||Lorenzo Tallarigo||Insider||Buy||75,417||GBX 4||£3,016.68|
|10/25/2016||Lorenzo Tallarigo||Insider||Buy||77,864||GBX 3||£2,335.92|
|9/26/2016||Lorenzo Tallarigo||Insider||Buy||79,988||GBX 3||£2,399.64|
|8/25/2016||Tallarigo ,Lorenzo||Insider||Buy||62,257||GBX 4||£2,490.28|
|7/25/2016||Tallarigo ,Lorenzo||Insider||Buy||63,351||GBX 4||£2,534.04|
|6/24/2016||Tallarigo ,Lorenzo||Insider||Buy||62,847||GBX 4||£2,513.88|
|5/13/2016||Diggle ,Martin||Insider||Buy||42,072||GBX 5||£2,103.60|
|5/12/2016||Diggle ,Martin||Insider||Buy||45,428||GBX 5||£2,271.40|
|5/5/2016||Diggle ,Martin||Insider||Buy||12,500||GBX 6||£750|
|5/4/2016||Diggle ,Martin||Insider||Buy||44,689||GBX 6||£2,681.34|
|5/3/2016||Diggle ,Martin||Insider||Buy||317,382||GBX 6||£19,042.92|
|4/22/2016||Tallarigo ,Lorenzo||Insider||Buy||41,083||GBX 6||£2,464.98|
|3/24/2016||Tallarigo ,Lorenzo||Insider||Buy||41,550||GBX 6||£2,493|
|2/26/2016||Diggle ,Martin||Insider||Buy||29,345||GBX 7||£2,054.15|
|2/25/2016||Tallarigo ,Lorenzo||Insider||Buy||36,370||GBX 7||£2,545.90|
|2/24/2016||Diggle ,Martin||Insider||Buy||46,693||GBX 6||£2,801.58|
|7/1/2015||Diggle ,Martin||Insider||Buy||284,439||GBX 0.09||£256|
|6/30/2015||Diggle ,Martin||Insider||Buy||775,000||GBX 0.09||£697.50|
|6/19/2015||Diggle ,Martin||Insider||Buy||225,000||GBX 0.08||£180|
|6/12/2015||Martin Diggle||Insider||Buy||283,978||GBX 9.01||£25,586.42|
|6/11/2015||Martin Diggle||Insider||Buy||416,022||GBX 9||£37,441.98|
|6/9/2015||Daniel Soland||Insider||Buy||500,000||GBX 9.45||£47,250|
|5/21/2015||Andrew Heath||Insider||Buy||100,000||GBX 10.60||£10,600|
|5/19/2015||Tim Watts||Insider||Buy||194,174||GBX 10.30||£19,999.92|
Headline Trends for Oxford BioMedica plc (LON:OXB)
Latest Headlines for Oxford BioMedica plc (LON:OXB)
Oxford BioMedica plc (OXB) Chart for Tuesday, May, 30, 2017